应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02256 和誉-B
交易中 07-15 15:18:24
9.780
-0.060
-0.61%
最高
10.100
最低
9.620
成交量
239.10万
今开
9.800
昨收
9.840
日振幅
4.88%
总市值
65.82亿
流通市值
65.82亿
总股本
6.73亿
成交额
2,359万
换手率
0.36%
流通股本
6.73亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
和誉-B07月14日获主力加仓2.7万元
市场透视 · 07-14 08:15
和誉-B07月14日获主力加仓2.7万元
和誉-B07月11日主力净流入90.7万元 散户资金抛售
市场透视 · 07-11
和誉-B07月11日主力净流入90.7万元 散户资金抛售
【券商聚焦】平安证券维持和誉(02256)“推荐”评级 机构指匹米替尼CSF-1R抑制剂展现了突出的临床潜力
金吾财讯 · 07-10
【券商聚焦】平安证券维持和誉(02256)“推荐”评级 机构指匹米替尼CSF-1R抑制剂展现了突出的临床潜力
中金:维持和誉-B(02256)“跑赢行业”评级 升目标价至11.3港元
智通财经 · 07-10
中金:维持和誉-B(02256)“跑赢行业”评级 升目标价至11.3港元
和誉-B盘中异动 早盘股价大涨5.00%报10.080港元
市场透视 · 07-10
和誉-B盘中异动 早盘股价大涨5.00%报10.080港元
和誉-B07月07日主力净流出232.3万元 散户资金买入
市场透视 · 07-07
和誉-B07月07日主力净流出232.3万元 散户资金买入
和誉-B(02256)7月4日斥资206.03万港元回购20万股
智通财经 · 07-04
和誉-B(02256)7月4日斥资206.03万港元回购20万股
和誉-B盘中异动 股价大跌5.06%
市场透视 · 07-04
和誉-B盘中异动 股价大跌5.06%
和誉-B07月02日主力净流入125.8万元 散户资金抛售
市场透视 · 07-02
和誉-B07月02日主力净流入125.8万元 散户资金抛售
和誉-B(02256)6月27日斥资200.8万港元回购20万股
智通财经 · 06-27
和誉-B(02256)6月27日斥资200.8万港元回购20万股
和誉-B06月26日遭主力抛售303.8万元
市场透视 · 06-26
和誉-B06月26日遭主力抛售303.8万元
和誉-B(02256.HK):将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌的最新2期临床试验数据
格隆汇 · 06-26
和誉-B(02256.HK):将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌的最新2期临床试验数据
和誉-B06月23日遭主力抛售240.5万元
市场透视 · 06-23
和誉-B06月23日遭主力抛售240.5万元
和誉-B(02256.HK):完成治疗软骨发育不全观察性研究的首例患者入组
格隆汇 · 06-23
和誉-B(02256.HK):完成治疗软骨发育不全观察性研究的首例患者入组
和誉-B(02256)6月20日斥资102.4万港元回购10万股
智通财经 · 06-20
和誉-B(02256)6月20日斥资102.4万港元回购10万股
港股公告掘金 | 中国软件国际首发鸿云虚拟机
智通财经 · 06-16
港股公告掘金 | 中国软件国际首发鸿云虚拟机
港股异动 | 和誉-B(02256)盘中涨超9% 匹米替尼上市申请获受理 授权合作显著带动业绩增长
智通财经 · 06-16
港股异动 | 和誉-B(02256)盘中涨超9% 匹米替尼上市申请获受理 授权合作显著带动业绩增长
和誉-B盘中异动 股价大涨5.08%报10.760港元
市场透视 · 06-16
和誉-B盘中异动 股价大涨5.08%报10.760港元
和誉-B(02256.HK):完成依帕戈替尼治疗HCC的注册性临床试验的首例患者给药
格隆汇 · 06-16
和誉-B(02256.HK):完成依帕戈替尼治疗HCC的注册性临床试验的首例患者给药
6亿美金!国产腱鞘巨细胞瘤新药报上市
药渡 · 06-14
6亿美金!国产腱鞘巨细胞瘤新药报上市
加载更多
公司概况
公司名称:
和誉-B
所属市场:
SEHK
上市日期:
--
主营业务:
和誉开曼有限责任公司是一家临床阶段生物制药公司。该公司致力于发现和开发创新差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011和 ABSK091,以及12款其他在研产品。ABSK011是一种强效且高选择性的成纤维细胞生长因子受体4(FGFR4) 小分子抑制剂。ABSK091 是一种分子靶向候选产品,也是 FGFR亚型 1、2和3的强效和选择性抑制剂。该公司的产品主要用于肝细胞癌(HCC)、尿路上皮癌(UC) 和胃癌(GC)。
发行价格:
--
{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":9.78,"timestamp":1752563870530,"preClose":9.84,"halted":0,"volume":2391000,"delay":0,"floatShares":673000000,"shares":673000000,"eps":0.048831088642572296,"marketStatus":"交易中","change":-0.06,"latestTime":"07-15 15:18:24","open":9.8,"high":10.1,"low":9.62,"amount":23590135,"amplitude":0.04878,"askPrice":9.81,"askSize":9000,"bidPrice":9.78,"bidSize":15000,"shortable":0,"etf":0,"ttmEps":0.04375436188651992,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1752567000000},"marketStatusCode":2,"adr":0,"listingDate":1634054400000,"exchange":"SEHK","adjPreClose":9.84,"openAndCloseTimeList":[[1752543000000,1752552000000],[1752555600000,1752566400000]],"volumeRatio":0.617217,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256","defaultTab":"news","newsList":[{"id":"2551901910","title":"和誉-B07月14日获主力加仓2.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551901910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551901910?lang=zh_cn&edition=full","pubTime":"2025-07-14 16:15","pubTimestamp":1752480954,"startTime":"0","endTime":"0","summary":"07月14日, 和誉-B股价涨0.82%,报收9.84元,成交金额1281.6万元,换手率0.19%,振幅2.97%,量比0.28。和誉-B今日主力资金净流入2.7万元,上一交易日主力净流入90.7万元。该股近5个交易日下跌1.51%,主力资金累计净流出89.4万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流出822.9万元,其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714170848a6a85864&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714170848a6a85864&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2550993632","title":"和誉-B07月11日主力净流入90.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2550993632","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550993632?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:15","pubTimestamp":1752221743,"startTime":"0","endTime":"0","summary":"07月11日, 和誉-B股价涨0.21%,报收9.76元,成交金额2012.1万元,换手率0.31%,振幅4.62%,量比0.44。和誉-B今日主力资金净流入90.7万元,上一交易日主力净流出191.8万元。该股近5个交易日下跌4.29%,主力资金累计净流出324.3万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流出296.0万元,其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711170326a444710a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711170326a444710a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2550616388","title":"【券商聚焦】平安证券维持和誉(02256)“推荐”评级 机构指匹米替尼CSF-1R抑制剂展现了突出的临床潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2550616388","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550616388?lang=zh_cn&edition=full","pubTime":"2025-07-10 15:25","pubTimestamp":1752132322,"startTime":"0","endTime":"0","summary":"匹米替尼CSF-1R抑制剂展现了突出的临床潜力,其全球Ⅲ期MANEUVER研究顶线结果证实,在腱鞘巨细胞瘤治疗中达到了高达54%的客观缓解率,对比安慰剂组仅3.2%,疗效优势显著。该机构表示,公司核心品种匹米替尼国内上市申请中,FGFR4抑制剂治疗肝癌已进入注册性临床试验,且持续推进早期在研管线进展。维持“推荐”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1962014","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256","CSF","161027"],"gpt_icon":0},{"id":"2550695718","title":"中金:维持和誉-B(02256)“跑赢行业”评级 升目标价至11.3港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550695718","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550695718?lang=zh_cn&edition=full","pubTime":"2025-07-10 10:43","pubTimestamp":1752115416,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,中金发布研报称,维持和誉-B2025年/2026年归母净利润预测0.45亿元/3.20亿元不变。考虑到依帕戈替尼数据优异及国内注册临床进展,和匹米替尼申报进展,该行维持“跑赢行业”评级,基于DCF模型,该行上调目标价22.8%至11.3港元,较当前股价有17.7%的上行空间。其中在免疫检查点治疗经治患者中,ORR达52.9%,mPFS为8.3个月。此前,匹米替尼已经获得授予优先审评资格和突破性疗法认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1316060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中金:维持和誉-B(02256)“跑赢行业”评级 升目标价至11.3港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256"],"gpt_icon":0},{"id":"2550469828","title":"和誉-B盘中异动 早盘股价大涨5.00%报10.080港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550469828","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550469828?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:42","pubTimestamp":1752111761,"startTime":"0","endTime":"0","summary":"2025年07月10日早盘09时42分,和誉-B股票出现波动,股价快速上涨5.00%。截至发稿,该股报10.080港元/股,成交量88.4万股,换手率0.13%,振幅3.23%。资金方面,该股资金流入236.04万港元,流出239.62万港元。和誉-B股票所在的生物技术行业中,整体涨幅为0.75%。其相关个股中,和誉-B、北海康成-B、来凯医药-B涨幅较大,振幅较大的相关个股有来凯医药-B、博安生物、北海康成-B,振幅分别为6.04%、5.98%、5.80%。该公司拥有两款核心候选产品ABSK011和 ABSK091,以及12款其他在研产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710094241a4416490&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710094241a4416490&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2549533559","title":"和誉-B07月07日主力净流出232.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2549533559","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549533559?lang=zh_cn&edition=full","pubTime":"2025-07-07 16:15","pubTimestamp":1751876155,"startTime":"0","endTime":"0","summary":"07月07日, 和誉-B股价跌2.92%,报收9.96元,成交金额2539.9万元,换手率0.37%,振幅5.85%,量比0.83。和誉-B今日主力资金净流出232.3万元,上一交易日主力净流入47.6万元。该股近5个交易日下跌0.99%,主力资金累计净流出397.6万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流入812.1万元,其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707170138a43b77c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707170138a43b77c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2548063367","title":"和誉-B(02256)7月4日斥资206.03万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2548063367","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548063367?lang=zh_cn&edition=full","pubTime":"2025-07-04 18:10","pubTimestamp":1751623848,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B(02256)发布公告,于2025年7月4日,该公司斥资206.03万港元回购20万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1314128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2548330647","title":"和誉-B盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548330647","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548330647?lang=zh_cn&edition=full","pubTime":"2025-07-04 10:41","pubTimestamp":1751596898,"startTime":"0","endTime":"0","summary":"2025年07月04日早盘10时41分,和誉-B股票出现波动,股价快速跳水5.06%。截至发稿,该股报10.140港元/股,成交量69.8万股,换手率0.10%,振幅6.18%。资金方面,该股资金流入185.548万港元,流出404.104万港元。和誉-B股票所在的生物技术行业中,整体涨幅为0.01%。该公司拥有两款核心候选产品ABSK011和 ABSK091,以及12款其他在研产品。ABSK091 是一种分子靶向候选产品,也是 FGFR亚型 1、2和3的强效和选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704104138a72dd2af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704104138a72dd2af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2548864212","title":"和誉-B07月02日主力净流入125.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2548864212","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548864212?lang=zh_cn&edition=full","pubTime":"2025-07-02 16:15","pubTimestamp":1751444108,"startTime":"0","endTime":"0","summary":"07月02日, 和誉-B股价涨3.13%,报收10.54元,成交金额1984.6万元,换手率0.28%,振幅4.31%,量比0.75。和誉-B今日主力资金净流入125.8万元,上一交易日主力净流出259.3万元。该股近5个交易日上涨1.33%,主力资金累计净流出1033.6万元;近20日主力资金累计净流入208.2万元,其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702165949a4cad01d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702165949a4cad01d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2546746643","title":"和誉-B(02256)6月27日斥资200.8万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2546746643","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546746643?lang=zh_cn&edition=full","pubTime":"2025-06-27 20:55","pubTimestamp":1751028943,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B(02256)发布公告,该公司于2025年6月27日斥资200.8万港元回购20万股股份,每股回购价格为10.02-10.1港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1311186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2546852733","title":"和誉-B06月26日遭主力抛售303.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546852733","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546852733?lang=zh_cn&edition=full","pubTime":"2025-06-26 20:25","pubTimestamp":1750940756,"startTime":"0","endTime":"0","summary":"06月26日, 和誉-B股价跌3.02%,报收10.28元,成交金额1998.1万元,换手率0.29%,振幅3.96%,量比0.68。和誉-B今日主力资金净流出303.8万元,连续5日净流出,上一交易日主力净流出210.6万元。该股近5个交易日上涨2.80%,主力资金累计净流出960.4万元;近20日主力资金累计净流入2195.4万元,其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626203503a71ee581&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626203503a71ee581&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2546522272","title":"和誉-B(02256.HK):将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌的最新2期临床试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2546522272","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546522272?lang=zh_cn&edition=full","pubTime":"2025-06-26 08:05","pubTimestamp":1750896337,"startTime":"0","endTime":"0","summary":"格隆汇6月26日丨和誉-B发布公告,公司的附属公司上海和誉生物医药科技有限公司宣布将在2025年欧洲肿瘤内科学会胃肠道肿瘤大会上汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌患者的最新2期临床试验数据。这些结果进一步证明了依帕戈替尼在既往接受过治疗和未接受治疗情况下的临床益处,为晚期HCC患者带来了新的希望。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/26080551312713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2488822045.USD","BK1161","BK1141","03347","BK1583","BK1576","02256"],"gpt_icon":0},{"id":"2545929164","title":"和誉-B06月23日遭主力抛售240.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545929164","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545929164?lang=zh_cn&edition=full","pubTime":"2025-06-23 16:15","pubTimestamp":1750666546,"startTime":"0","endTime":"0","summary":"06月23日, 和誉-B股价跌1.16%,报收10.26元,成交金额2795.3万元,换手率0.40%,振幅3.85%,量比0.43。和誉-B今日主力资金净流出240.5万元,上一交易日主力净流出91.2万元。该股近5个交易日下跌5.35%,主力资金累计净流入299.4万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流入3366.8万元,其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623172308a7186fab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623172308a7186fab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","02256","BK1161"],"gpt_icon":0},{"id":"2545978451","title":"和誉-B(02256.HK):完成治疗软骨发育不全观察性研究的首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2545978451","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545978451?lang=zh_cn&edition=full","pubTime":"2025-06-23 08:07","pubTimestamp":1750637262,"startTime":"0","endTime":"0","summary":"格隆汇6月23日丨和誉-B(02256.HK)宣布,一项在软骨发育不全(“ACH”)儿童中开展的观察性研究完成首例患者入组。这项研究将为高选择性小分子FGFR2/3抑制剂ABSK061治疗ACH的研究收集患者的基线信息。今年3月,ABSK061获中国国家药品监督管理局药品审评中心批准IND申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/23080751230851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2544228111","title":"和誉-B(02256)6月20日斥资102.4万港元回购10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2544228111","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544228111?lang=zh_cn&edition=full","pubTime":"2025-06-20 20:06","pubTimestamp":1750421212,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B(02256)发布公告,于2025年6月20日斥资102.4万港元回购10万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1307943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2543160155","title":"港股公告掘金 | 中国软件国际首发鸿云虚拟机","url":"https://stock-news.laohu8.com/highlight/detail?id=2543160155","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543160155?lang=zh_cn&edition=full","pubTime":"2025-06-16 23:02","pubTimestamp":1750086173,"startTime":"0","endTime":"0","summary":"【重大事项】中国软件国际(00354)首发鸿云虚拟机亚盛医药-B(06855)多项研究进展亮相2025年欧洲血液学协会年会(EHA)科济药业-B(02171)于2025年EHA年会上呈列的CT071的研究结果和誉-B(02256):和誉医药完成依帕戈替尼治疗HCC的注册性临床试验的首例患者给药中国生物制药(01177):TDI01混悬液“ROCK2抑制剂”新适应症被CDE纳入突破性治疗药物程序重庆","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1305975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1586","BK1587","BK1515","02171","BK1526","IE00BZ08YT58.USD","BK1225","BK1518","01053","BK1594","BK1161","BK1521","HSCEI","IE00BZ08YS42.EUR","BK1191","BK1155","HSTECH","IE00BZ08YR35.GBP","BK1589","BK1568","02256","YANG","00354","LU2488822045.USD","BK4614","BK1574","BK1585"],"gpt_icon":1},{"id":"2543490096","title":"港股异动 | 和誉-B(02256)盘中涨超9% 匹米替尼上市申请获受理 授权合作显著带动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2543490096","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543490096?lang=zh_cn&edition=full","pubTime":"2025-06-16 11:37","pubTimestamp":1750045062,"startTime":"0","endTime":"0","summary":"消息面上,6月10日,和誉医药宣布,中国国家药品监督管理局已受理其自主研发的CSF-1R高选择性小分子抑制剂匹米替尼的新药上市申请,将其作为治疗成人腱鞘巨细胞瘤患者的1类创新药。此外,公司近日宣布,附属和誉医药已收到默克根据授权协议支付的匹米替尼全球商业化选择权行权费8500万美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1305544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 和誉-B(02256)盘中涨超9% 匹米替尼上市申请获受理 授权合作显著带动业绩增长","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2543645141","title":"和誉-B盘中异动 股价大涨5.08%报10.760港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2543645141","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543645141?lang=zh_cn&edition=full","pubTime":"2025-06-16 09:43","pubTimestamp":1750038228,"startTime":"0","endTime":"0","summary":"2025年06月16日早盘09时43分,和誉-B股票出现异动,股价快速拉升5.08%。截至发稿,该股报10.760港元/股,成交量83.8万股,换手率0.12%,振幅4.49%。资金方面,该股资金流入533.344万港元,流出238.264万港元。和誉-B股票所在的生物技术行业中,整体跌幅为0.76%。该公司拥有两款核心候选产品ABSK011和 ABSK091,以及12款其他在研产品。ABSK091 是一种分子靶向候选产品,也是 FGFR亚型 1、2和3的强效和选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250616094348951dfc61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250616094348951dfc61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2543612299","title":"和誉-B(02256.HK):完成依帕戈替尼治疗HCC的注册性临床试验的首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2543612299","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543612299?lang=zh_cn&edition=full","pubTime":"2025-06-16 08:06","pubTimestamp":1750032361,"startTime":"0","endTime":"0","summary":"格隆汇6月16日丨和誉-B(02256.HK)宣布已完成其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼治疗肝细胞癌(“HCC”)的注册性临床试验的首例患者给药。依帕戈替尼于2025年5月获中国国家药品监督管理局药品审评中心突破性疗法认定。依帕戈替尼也是首个采用靶向分子生物标志物精准治疗HCC的药物。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/16080651084797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02256","HCC","BK4006","LU2488822045.USD","BK1161","BK1576","03347","BK1141","BK1583"],"gpt_icon":0},{"id":"2543693296","title":"6亿美金!国产腱鞘巨细胞瘤新药报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2543693296","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543693296?lang=zh_cn&edition=full","pubTime":"2025-06-15 07:31","pubTimestamp":1749943888,"startTime":"0","endTime":"0","summary":"近日,和誉医药自主研发的首款国产CSF-1R抑制剂盐酸匹米替尼胶囊,正式提交新药上市申请,用于需要系统性治疗的腱鞘巨细胞瘤成人患者。目前,全球范围内获批用于治疗腱鞘巨细胞瘤的药物屈指可数。一旦获批上市,匹米替尼将为国内腱鞘巨细胞瘤患者带来全新、高效且安全的治疗选择,显著改善患者生活质量,减轻病痛折磨。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250615073619a709b110&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250615073619a709b110&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","LU2488822045.USD","06978","BK1574","BK1161","02256","09939"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":-0.012},{"period":"1month","weight":-0.0391},{"period":"3month","weight":0.3743},{"period":"6month","weight":1.3429},{"period":"1year","weight":2.0464},{"period":"ytd","weight":1.1391}],"compareEarnings":[{"period":"1week","weight":0.0132},{"period":"1month","weight":0.013},{"period":"3month","weight":0.1275},{"period":"6month","weight":0.255},{"period":"1year","weight":0.3231},{"period":"ytd","weight":0.2065}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家临床阶段生物制药公司。该公司致力于发现和开发创新差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011和 ABSK091,以及12款其他在研产品。ABSK011是一种强效且高选择性的成纤维细胞生长因子受体4(FGFR4) 小分子抑制剂。ABSK091 是一种分子靶向候选产品,也是 FGFR亚型 1、2和3的强效和选择性抑制剂。该公司的产品主要用于肝细胞癌(HCC)、尿路上皮癌(UC) 和胃癌(GC)。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.143011},{"month":2,"riseRate":0.75,"avgChangeRate":0.046576},{"month":3,"riseRate":0.5,"avgChangeRate":0.054417},{"month":4,"riseRate":0.25,"avgChangeRate":-0.010041},{"month":5,"riseRate":0.25,"avgChangeRate":0.029375},{"month":6,"riseRate":0.5,"avgChangeRate":0.006841},{"month":7,"riseRate":0.5,"avgChangeRate":0.027703},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.050943},{"month":9,"riseRate":0.666667,"avgChangeRate":0.042883},{"month":10,"riseRate":0.666667,"avgChangeRate":0.004984},{"month":11,"riseRate":0.75,"avgChangeRate":0.204437},{"month":12,"riseRate":0,"avgChangeRate":-0.093315}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}